Innate Pharma, Sanofi expand collaboration for NK cell therapeutics

Innate Pharma (IPHA) and Sanofi (SNY) announced an expansion of their collaboration, with Sanofi licensing a natural killer, or NK, cell engager program targeting B7H3 from Innate’s ANKET platform. Sanofi will also have the option to add up to two additional ANKET targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization. Innate and Sanofi signed a first NK cell engagers collaboration in 2016 for the generation and evaluation of up to two bispecific NK cell engagers, which are currently being evaluated by Sanofi’s R&D team, with one of these molecules already in clinical studies.